Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876725 | 0.78 | PIK3CD (0.40) | PIK3CDCYP2D6CYP3A4CYP1A2SMN1; SMN2 | |
| SCHEMBL25876724 | 0.77 | PIK3CD (0.33) | PIK3CDCYP2D6CYP3A4CYP1A2SMN1; SMN2 | |
| SCHEMBL19852847 | 0.75 | OTUD7B (0.44) | PIK3CDOTUD7BCYP2D6CYP3A4CYP1A2 | |
| SCHEMBL19851165 | 0.74 | OTUD7B (0.36) | OTUD7B | |
| SCHEMBL19851168 | 0.73 | SIGMAR1 (0.46) | CYP2D6CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL13703126 | 0.73 | OTUD7B (0.45) | PIK3CDOTUD7BCYP2D6CYP3A4SMN1; SMN2 | |
| SCHEMBL19851210 | 0.72 | CHRNB2 (0.32) | OTUD7B | |
| SCHEMBL21104769 | 0.71 | — | — | |
| SCHEMBL10232766 | 0.70 | CRBN (0.42) | PIK3CDCYP2D6SMN1; SMN2 | |
| SCHEMBL19851170 | 0.70 | HSD17B10 (0.35) | OTUD7BCYP2D6CYP3A4USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| US-11376250-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210322406-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-10-21 | — | — | US | disclosed |
| US-10918637-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2021021996-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | APTINYX INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20190175588-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-06-13 | — | — | US | disclosed |
| WO-2018026782-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376250-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | PIK3CD 1900/4885OTUD7B 3931/4885CYP2D6 671/4885 |
| US-20190175588-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | PIK3CD 1900/4885OTUD7B 3931/4885CYP2D6 671/4885 |
| US-20210322406-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | PIK3CD 1900/4885OTUD7B 3931/4885CYP2D6 671/4885 |
| US-10918637-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | PIK3CD 1900/4885OTUD7B 3931/4885CYP2D6 671/4885 |
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | ACE, ACE2, PREP | PIK3CD 4354/4885OTUD7B 702/4885CYP2D6 628/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | PIK3CD 4557/4885OTUD7B 2072/4885CYP2D6 3390/4885 |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | PIK3CD 1900/4885OTUD7B 3931/4885CYP2D6 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.